115115-40-7

Usage

Uses

Used in Pharmaceutical Research:
(R)-1-(N-benzyloxycarbonylamino)ethylphosphinic acid is used as a research compound for studying its potential as an enzyme inhibitor. Its unique structure allows it to target enzymes involved in the biosynthesis of amino acids and other metabolic processes, which could lead to the development of new treatments for various diseases and conditions.
Used in Drug Development:
In the pharmaceutical industry, (R)-1-(N-benzyloxycarbonylamino)ethylphosphinic acid is used as a lead compound in the development of new drugs. Its potential to inhibit enzymes makes it a valuable starting point for designing drugs that could treat cancer and microbial infections, among other conditions.
Used in Medicinal Chemistry:
(R)-1-(N-benzyloxycarbonylamino)ethylphosphinic acid serves as a subject of study in medicinal chemistry, where researchers investigate its specific properties and potential therapeutic uses. This knowledge can contribute to the advancement of drug discovery and the development of novel therapeutic agents.
Used in Enzyme Inhibition Studies:
(R)-1-(N-benzyloxycarbonylamino)ethylphosphinic acid is used as a tool in enzyme inhibition studies, particularly for enzymes involved in amino acid biosynthesis and other metabolic pathways. Understanding its interactions with these enzymes can provide insights into the development of targeted therapies for various diseases.
Used in Cancer Treatment Research:
In the field of oncology, (R)-1-(N-benzyloxycarbonylamino)ethylphosphinic acid is used as a potential therapeutic agent for cancer treatment. Its ability to inhibit enzymes involved in metabolic processes may offer new avenues for treating cancer and improving patient outcomes.
Used in Microbial Infection Treatment:
(R)-1-(N-benzyloxycarbonylamino)ethylphosphinic acid is also used in the development of treatments for microbial infections. Its potential to inhibit enzymes essential for microbial growth and survival makes it a valuable compound for exploring new antimicrobial therapies.

Upstream product

• 108327-37-3 [1-[[(phenylmethoxy)carbonyl]amino]ethyl]phosphinic acid 
• 4132-86-9 N-benzyloxycarbonylalanine 
• 868523-17-5 (2-benzyloxycarbonylamino-ethyl)-H-phosphinic acid 

Downstream Products

• 287935-86-8 methyl 2(R,S)-benzyl-3-{hydroxy[1'(R)-(N-benzyloxycarbonylamino)ethyl]phosphinyl}propanoate 
• 374075-34-0 (S)-3-[((R)-1-Benzyloxycarbonylamino-ethyl)-hydroxy-phosphinoyl]-2-biphenyl-4-ylmethyl-propionic acid ethyl ester 
• 583866-45-9 (2S)-2-({[(1S)-2-amino-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino}carbonyl)pent-4-ynyl ((1R)-1-{[(benzyloxy)carbonyl]amino}ethyl)phosphinic acid 
• 287935-81-3 2(R,S)-benzyl-3-{hydroxy[1'(R)-(N-benzyloxycarbonylamino)ethyl]phosphinyl}propanoic acid 
• 287935-87-9 2(R,S)-benzyl-3-{hydroxy[1'(R)-(N-benzyloxycarbonylamino)ethyl]phosphinyl}propanoyl-L-tyrosine 
• 287935-83-5 2(R,S)-benzyl-3-{hydroxy[1'(R)-(N-benzyloxycarbonylamino)ethyl]phosphinyl}propanoyl-L-3-iodotyrosine methyl ester 
• 287935-88-0 2(R,S)-benzyl-3-{hydroxy[1'(R)-(N-benzyloxycarbonylamino)ethyl]phosphinyl}propanoyl-L-3-iodotyrosine 
• 287935-82-4 2(R,S)-benzyl-3-{hydroxy[1'(R)-(N-benzyloxycarbonylamino)ethyl]phosphinyl}propanoyl-L-tyrosine benzyl ester 
• 113592-76-0 methyl <1-(R)-<(benzyloxycarbonyl)amino>ethyl>phosphinate 
• 1206514-66-0 C₃₃H₃₄NO₆P 

Relevant academic research and scientific papers

Penicillin G acylase-mediated kinetic resolution of racemic 1-(N-acylamino)alkylphosphonic and 1-(N-acylamino)alkylphosphinic acids and their esters

Extensive studies on the penicillin G acylase-mediated kinetic resolution of N-acylated 1-aminoalkylphosphonic and 1-aminoalkylphosphinic acids as well as their esters were carried out to recognise the relationships between the substrate structure, reacti

AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN

The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(═O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(═O)—O—C(R8)(R9)—OC(═O)—R10 group; R2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R3 represents a hydrogen atom or a —C(R12)(R13)—OC(═O)—R14 group; R4 and R5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R4 represents a hydrogen atom and R5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substituted; and R7 represents a hydrogen atom or a benzyl, alkyl, heteroaryl, alkylheteroaryl, —CHMe—COOR18, —CHR19—OC(═O)OR20 and —CHR19—OC(═O)OR20 group. The present invention also relates to the use of these compounds as a medicinal product, and in particular for the treatment of pain, more advantageously neuropathic and neuroinflammatory pain, to their method of synthesis and also to the compositions containing them.

(α-aminophosphino) peptides derivative and compositions containing same

The invention concerns (α-aminophosphino) peptide derivative compounds of general formula (I) wherein: R1and R2represent each a hydrogen atom or together form an imine with the adjacent nitrogen atom; R3represents an alkyl

Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor

A series of phosphinic compounds mimicking the transition state of substrates hydrolysed by aminopeptidase N (EC 3.4.11.2) were synthesized. These new compounds have potent inhibitory activities with Ki values in the nanomolar range. These derivatives behave as the most potent APN inhibitors designed to date.